Contact Informatie voor patiƫnten Enrolment new DCCG study Menu

KEYNOTE-177

Acronym

KEYNOTE-177

Name of the study

A phase III study of first-line Pembrolizumab (MK-3475) versus chemotherapy in microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal carcinoma

Researchers and contact information

. AMC Amsterdam: prof.dr. C.J.A. Punt,

E-mail c.punt@amc.nl

. UMC Utrecht: dr. M. Koopman,

E-mail m.koopman-6@umcutrecht.nl

. UMC Groningen: prof.dr. G.A.P. Hospers,

E-mail g.a.p.hospers@umcg.nl

. Isala Klinieken Zwolle: dr. J.W.B. de Groot,

E-mail j.w.b.de.groot@isala.nl

Summary study

Pembrolizumab versus chemotherapy in microsatellite instability -high or mismatch repair deficient metastatic colorectal carcinoma

Intervention

Experimental arm: pembrolizumab

Control arm, investigator's choice of the following:

. mFOLFOX6

. mFOLFOX6 + bevacizumab or cetuximab

. FOLFIRI

. FOLFIRI + bevacizumab or cetuximab

Documents